Meta-analysis: Antiarrhythmic versus control
DISEASE INTERVENTION COMPARISON RESULTS
Cochrane Database Syst Rev. 2007;0(4):CD005049 Systematic Review, Cochrane Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To improve mortality: class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
Arch Intern Med. 2006 Apr 10;166(7):719-28 Systematic Review
IN atrial fibrillation, rhythm control strategy The Use of
antiarrhythmic drugs, classes IA, IC, III
As Treatment, Chronic
Is worse Than
placebo or no treatment
To reduce mortality, class IA drugs (quinidine, dysopiramide) increased mortality (NNH 109) and the rest did not modify it. All drugs increased adverse effects and pro-arrhythmia (but amiodarone).
Circulation. 1990 Oct;82(4):1106-16 Meta-Analysis
IN StudyID: Coplen 1990, atrial fibrillation, pro-arrhythmia The Use of
quinidine
As Treatment, Chronic
Is worse Than
placebo
To overall unajusted mortality at 1 year: 2.9% in intv. vs 0.8% in cont. Patients remaining in sinus rhythm at 1 year were: 50% in intv. vs 24% in cont.
J Fam Pract 2000 Nov;49(11):1033-46 Meta-Analysis
IN StudyID: Miller 2000, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs
As -
Is better Than
placebo or rate control
To maintining sinus rhythm. Not data about mortality or adverse effects.
Heart 2002 Jun;87(6):535-43 Meta-Analysis
IN StudyID: Nichol 2002, atrial fibrillation, existing meta-analysis The Use of
diverse antiarrhythmic drugs, grouped by classes
As Treatment, Acute
Is better Than
placebo
To converting AF to sinus rhythm. At a median follow-up of 24 hr, median proportion of patients in sinus rhythm was 55% in intv. and 32% in cont.